Skip to main content

Table 4 Terminal measurements of bone marrow cell recipients with post hoc P values

From: Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease

Week 12 Healthy + DMEM BMC recipients ( n = 5) Healthy + pravastatin BMC recipients ( n = 5) CKD + DMEM BMC recipients ( n = 10) CKD + pravastatin BMC recipients ( n = 9) CKD + DMEM BMC vs. healthy + DMEM BMC CKD + DMEM BMC vs. CKD + pravastatin BMC
Body weight (g) 376 ± 23 379 ± 26 359 ± 38 373 ± 22 ns ns
Heart weight (g/100 g BW) 0.44 ± 0.07 0.44 ± 0.03 0.47 ± 0.08 0.44 ± 0.05 ns ns
Kidney weight (g/100 g BW) 0.59 ± 0.07 0.56 ± 0.05 0.53 ± 0.06 0.55 ± 0.04 0.063 ns
MAP (mmHg) 149 ± 28 146 ± 35 173 ± 21 153 ± 21 0.095 0.091
GFR (μl/minute/100 g) 371 ± 68 352 ± 119 237 ± 159 261 ± 149 0.057 ns
ERPF (μl/minute/100 g) 1538 ± 224 1388 ± 502 844 ± 626* 1157 ± 359 <0.05 ns
Hematocrit 0.45 ± 0.01 0.44 ± 0.01 0.42 ± 0.03* 0.46 ± 0.02 <0.05 <0.05
FF (%) 24.1 ± 2.4 26.2 ± 4.7 29.9 ± 4.5* 26.4 ± 3.7 <0.05 0.071
  1. Data presented as mean ± standard deviation. BMC, bone marrow cell; BW, body weight; CKD, chronic kidney disease; DMEM, Dulbecco’s modified Eagle medium; ERPF, effective renal plasma flow; FF, filtration fraction; GFR, glomerular filtration rate; MAP, mean arterial pressure. *P <0.05 compared with healthy BMC recipients, P <0.05 compared with CKD BMC recipients. Trends (P <0.1) are only indicated with the exact P value.